Hepatitis delta: virological and clinical aspects

Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira Dos Santos, Juan Miguel Villalobos Salcedo, Deusilene Souza Vieira, Luan Felipo Botelho-Souza, Mariana Pinheiro Alves Vasconcelos, Alcione de Oliveira Dos Santos, Juan Miguel Villalobos Salcedo, Deusilene Souza Vieira

Abstract

There are an estimated 400 million chronic carriers of HBV worldwide; between 15 and 20 million have serological evidence of exposure to HDV. Traditionally, regions with high rates of endemicity are central and northern Africa, the Amazon Basin, eastern Europe and the Mediterranean, the Middle East and parts of Asia. There are two types of HDV/HBV infection which are differentiated by the previous status infection by HBV for the individual. Individuals with acute HBV infection contaminated by HDV is an HDV/HBV co-infection, while individuals with chronic HBV infection contaminated by HDV represent an HDV/HBV super-infection. The appropriate treatment for chronic hepatitis delta is still widely discussed since it does not have an effective drug. Alpha interferon is currently the only licensed therapy for the treatment of chronic hepatitis D. The most widely used drug is pegylated interferon but only approximately 25% of patients maintain a sustained viral response after 1 year of treatment. The best marker of therapeutic success would be the clearance of HBsAg, but this data is rare in clinical practice. Therefore, the best way to predict a sustained virologic response is the maintenance of undetectable HDV RNA levels.

Keywords: Clinical aspects; HDV; Virology.

Conflict of interest statement

Ethics approval and consent to participate

Not applicable in this section.

Consent for publication

Not applicable in this section.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Schematic representation of HDV. The Hepatitis D virus wrapped in the HBV surface antigen. Outer HBsAg in black. With L (preS1 or large), M (preS2 or middle) and S (small) peripheral distribution of the three surface proteins. In the central portion, HDAg (HDAg-S and HDAg-L) is represented in blue and single-stranded RNA in red
Fig. 2
Fig. 2
HDV RNA editing mechanism. Genomic RNA (gray rounded rectangle) serves as a template for mRNA synthesis which is translated into HDAg-S, which is necessary for synthesis of new RNAs. The genome serves as a template for the synthesis of the antigenome (rounded black rectangle), which also serves as a template for new genomic RNAs. A fraction of antigenomic RNAs are edited by the enzyme adenosine deaminase (ADAR-1) at the UAG site (stop codon), also called the Amber/W site (wavy and dotted arrow), wherein an adenine is replaced by inosine. The edited antigenomes serve as templates for the edited genomes (rounded rectangle edited for ACC). Edited genomes serve to synthesize edited messenger RNAs (with UGG – Tryptophan instead of UAG-stop codon) encoding HDAg-L, which is the key factor for enveloping the virus and inhibiting replication. The edited genome and antigenomes are simultaneously synthesized by a replication mechanism called rolling-circle. This way the editing levels accumulate replication products. Note that the numbering scheme is intended to indicate an increasing repertoire of activities that persist as replication occurs, rather than a gradual progression in which the above processes are terminated. (Source: [28]. Curr Top MicrobiolImmunol, our translation, modified)
Fig. 3
Fig. 3
Structures of the two types of Delta antigen. (Source: [14], Journal of Virology, modified)
Fig. 4
Fig. 4
Schematic representation of HDV RNAs. Antigenome and genome of approximately 1700 nucleotides in a circular conformation (black). HDAg-S with 195 amino acids (orange) and HDAg-L with 214 amino acids (orange + blue). Negative polarity, the genome has an inverse orientation from the messenger RNA
Fig. 5
Fig. 5
Replication and assembly cycle diagram. (1) The virion adheres to the hepatocytes via an interaction between HbsAg-L and a membrane receptor that has not yet been characterized, in the host cell, (2) the virion enters the cell and loses its envelope. (3) The ribonucleoprotein (HDV RNA complexed to HDAg) is imported into the nucleus of the cell, (4) the genomic RNA is transcribed in the nucleus into mRNA and antigenomic RNA, which in turn serves as a template for new RNA genomic transcripts. (5) The mRNA is exported to the cytoplasm where it is translated into HDAg-S in the endoplasmic reticulum, (6) the new HDAg-S molecules return to the cell nucleus to support the replication of more RNA. The two forms of HDAg associate themselves with the new genomic RNA to form new ribonucleoproteins, (7) which are exported to the cytoplasm where they will interact with HBV envelope proteins through HDAg-L in the endoplasmic reticulum to form new viral particles. (8) These particles by budding in an intermediate compartment (9) are exported from the hepatocyte via the trans-Golgi network to re-infect new cells. (Source: [20], Lancet, modified)
Fig. 6
Fig. 6
Schematic representation of the clinical course of hepatitis Delta
Fig. 7
Fig. 7
Fluxogram for the diagnosis of hepatitis Delta

References

    1. Rizzetto M, Canese MG, Aricò S, Crivelli O, Trepo C, Bonino F, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. [Internet] 1977;18:997–1003. doi: 10.1136/gut.18.12.997.
    1. Canese MG, Rizzetto M, Arico S, Crivelli O, Zanetti AR, Macchiorlatti E, et al. An ultrastructural and immunohistochemical study on the delta antigen associated with the hepatitis B virus. J Pathol. [Internet] 1979;128:169–175. doi: 10.1002/path.1711280402.
    1. Rizzetto M, Canese MG, Gerin JL, London WT, Sly DL, Purcell RH. Transmission of the hepatitis B virus-associated delta antigen to chimpanzees. J Infect Dis. [Internet] 1980;141:590–602. doi: 10.1093/infdis/141.5.590.
    1. Rizzetto M, Purcell RH, Gerin JL. Epidemiology of HBV-associated delta agent: geographical distribution of anti-delta and prevalence in polytransfused HBsAg carriers. Lancet (London, England). [Internet] 1980;1:1215–1218. doi: 10.1016/S0140-6736(80)91678-5.
    1. Rizzetto M, Shih JW, Gerin JL. The hepatitis B virus-associated delta antigen: isolation from liver, development of solid-phase radioimmunoassays for delta antigen and anti-delta and partial characterization of delta antigen. J Immunol. [Internet] 1980;125:318–324.
    1. Smedile A, Rizzetto M. HDV: thirty years later. Dig Liver Dis. [Internet] 2011;43(Suppl 1):S15–S18. doi: 10.1016/S1590-8658(10)60687-1.
    1. Bonino F, Hoyer B, Ford E, Shih JW, Purcell RH, Gerin JL. The delta agent: HBsAg particles with delta antigen and RNA in the serum of an HBV carrier. Hepatology [Internet]. 1:127–31. Available from: . Cited 29 Mar 2016.
    1. Rizzetto M, Hoyer B, Canese MG, Shih JW, Purcell RH, Gerin JL. Delta agent: association of delta antigen with hepatitis B surface antigen and RNA in serum of delta-infected chimpanzees. Proc Natl Acad Sci USA. [Internet] 1980;77:6124–6128. doi: 10.1073/pnas.77.10.6124.
    1. Kos A, Dijkema R, Arnberg AC, van der Meide PH, Schellekens H. The hepatitis delta (delta) virus possesses a circular RNA. Nature. [Internet] 1986;323:558–560. doi: 10.1038/323558a0.
    1. Wu HN, Lin YJ, Lin FP, Makino S, Chang MF, Lai MM. Human hepatitis delta virus RNA subfragments contain an autocleavage activity. Proc Natl Acad Sci U S A. [Internet] 1989;86:1831–1835. doi: 10.1073/pnas.86.6.1831.
    1. Salehi-Ashtiani K, Lupták A, Litovchick A, Szostak JW. A genomewide search for ribozymes reveals an HDV-like sequence in the human CPEB3 gene. Science. [Internet] 2006;313:1788–1792.
    1. Branch AD, Benenfeld BJ, Baroudy BM, Wells FV, Gerin JL, Robertson HD. An ultraviolet-sensitive RNA structural element in a viroid-like domain of the hepatitis delta virus. Science. [Internet] 1989;243:649–652.
    1. Fu TB, Taylor J. The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J Virol. [Internet] 1993;67:6965–6972.
    1. Lai MMC. RNA replication without RNA-dependent RNA polymerase: surprises from hepatitis delta virus. J Virol. [Internet] 2005;79:7951–7958. doi: 10.1128/JVI.79.13.7951-7958.2005.
    1. Chang J, Nie X, Chang HE, Han Z, Taylor J. Transcription of hepatitis delta virus RNA by RNA polymerase II. J Virol. [Internet] 2008;82:1118–1127. doi: 10.1128/JVI.01758-07.
    1. Taylor JM. Structure and replication of hepatitis delta virus RNA. Curr Top Microbiol Immunol. [Internet] 2006;307:1–23.
    1. Rizzetto M. The adventure of delta. Liver Int. [Internet] 2016;36(Suppl 1):135–140. doi: 10.1111/liv.13018.
    1. Taylor JM. Hepatitis delta virus. Virology. [Internet] 2006;344:71–76. doi: 10.1016/j.virol.2005.09.033.
    1. Bonino F, Heermann KH, Rizzetto M, Gerlich WH. Hepatitis delta virus: protein composition of delta antigen and its hepatitis B virus-derived envelope. J Virol. [Internet] 1986;58:945–950.
    1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet (London, England). [Internet] 2011;378:73–85. doi: 10.1016/S0140-6736(10)61931-9.
    1. Wang KS, Choo QL, Weiner AJ, Ou JH, Najarian RC, Thayer RM, et al. Structure, sequence and expression of the hepatitis delta (delta) viral genome. Nature. [Internet] 1986;323:508–514. doi: 10.1038/323508a0.
    1. Kuo MY, Chao M, Taylor J. Initiation of replication of the human hepatitis delta virus genome from cloned DNA: role of delta antigen. J Virol. [Internet]. 1989;63:1945–50. Available from: .
    1. Wang T-C, Chao M. Molecular cloning and expression of the hepatitis delta virus genotype IIb genome. Biochem Biophys Res Commun. [Internet] 2003;303:357–363. doi: 10.1016/S0006-291X(03)00338-3.
    1. Makino S, Chang MF, Shieh CK, Kamahora T, Vannier DM, Govindarajan S, et al. Molecular cloning and sequencing of a human hepatitis delta (delta) virus RNA. Nature. [Internet] 1987;329:343–346. doi: 10.1038/329343a0.
    1. Glenn JS, White JM. Trans-dominant inhibition of human hepatitis delta virus genome replication. J Virol. [Internet] 1991;65:2357–2361.
    1. Sheu SY, Chen KL, Lee YW, Lo SJ. No intermolecular interaction between the large hepatitis delta antigens is required for the secretion with hepatitis B surface antigen: a model of empty HDV particle. Virology. [Internet] 1996;218:275–278. doi: 10.1006/viro.1996.0191.
    1. Sheu G-T. Initiation of hepatitis delta virus (HDV) replication: HDV RNA encoding the large delta antigen cannot replicate. J Gen Virol. [Internet] 2002;83:2507–2513. doi: 10.1099/0022-1317-83-10-2507.
    1. Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr Top Microbiol Immunol. [Internet] 2012;353:123–143.
    1. Casey JL. RNA editing in hepatitis delta virus. Curr Top Microbiol Immunol. [Internet] 2006;307:67–89.
    1. Casey JL, Bergmann KF, Brown TL, Gerin JL. Structural requirements for RNA editing in hepatitis delta virus: evidence for a uridine-to-cytidine editing mechanism. Proc Natl Acad Sci USA. [Internet] 1992;89:7149–7153. doi: 10.1073/pnas.89.15.7149.
    1. Casey JL, Gerin JL. Hepatitis D virus RNA editing: specific modification of adenosine in the antigenomic RNA. J Virol. [Internet] 1995;69:7593–7600.
    1. Chao YC, Chang MF, Gust I, Lai MM. Sequence conservation and divergence of hepatitis delta virus RNA. Virology. [Internet] 1990;178:384–392. doi: 10.1016/0042-6822(90)90335-O.
    1. Chang MF, Baker SC, Soe LH, Kamahora T, Keck JG, Makino S, et al. Human hepatitis delta antigen is a nuclear phosphoprotein with RNA-binding activity. J Virol. [Internet] 1988;62:2403–2410.
    1. Mu JJ, Wu HL, Chiang BL, Chang RP, Chen DS, Chen PJ. Characterization of the phosphorylated forms and the phosphorylated residues of hepatitis delta virus delta antigens. J Virol. [Internet] 1999;73:10540–10545.
    1. Mu J-J, Tsay Y-G, Juan L-J, Fu T-F, Huang W-H, Chen D-S, et al. The small delta antigen of hepatitis delta virus is an acetylated protein and acetylation of lysine 72 may influence its cellular localization and viral RNA synthesis. Virology. 2004;319:60–70. doi: 10.1016/j.virol.2003.10.024.
    1. Li Y-J, Stallcup MR, Lai MMC. Hepatitis delta virus antigen is methylated at arginine residues, and methylation regulates subcellular localization and RNA replication. J Virol. [Internet] 2004;78:13325–13334. doi: 10.1128/JVI.78.23.13325-13334.2004.
    1. Glenn JS, Watson JA, Havel CM, White JM. Identification of a prenylation site in delta virus large antigen. Science. [Internet] 1992;256:1331–1333.
    1. Huang WH, Chen CW, Wu HL, Chen PJ. Post-translational modification of delta antigen of hepatitis D virus. Curr Top Microbiol Immunol. [Internet] 2006;307:91–112.
    1. Huang C-R, Wang RYL, Hsu S-C, Lo SJ. Lysine-71 in the large delta antigen of hepatitis delta virus clade 3 modulates its localization and secretion. Virus Res. 2012;170:75–84. doi: 10.1016/j.virusres.2012.08.021.
    1. Hong S-Y, Chen P-J. Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II. J Virol. [Internet] 2010;84:1430–1438. doi: 10.1128/JVI.02083-09.
    1. Tan K-P, Shih K-N, Lo SJ. Ser-123 of the large antigen of hepatitis delta virus modulates its cellular localization to the nucleolus, SC-35 speckles or the cytoplasm. J Gen Virol [Internet] 2004;85:1685–1694. doi: 10.1099/vir.0.19690-0.
    1. Hong S-Y, Chen P-J. Phosphorylation of serine 177 of the small hepatitis delta antigen regulates viral antigenomic RNA replication by interacting with the processive RNA polymerase II. J Virol. [Internet] 2010;84:1430–1438. doi: 10.1128/JVI.02083-09.
    1. Mu JJ, Chen DS, Chen PJ. The conserved serine 177 in the delta antigen of hepatitis delta virus is one putative phosphorylation site and is required for efficient viral RNA replication. J Virol. [Internet] 2001;75:9087–9095. doi: 10.1128/JVI.75.19.9087-9095.2001.
    1. Sharmeen L, Kuo MY, Dinter-Gottlieb G, Taylor J. Antigenomic RNA of human hepatitis delta virus can undergo self-cleavage. J Virol. [Internet] 1988;62:2674–2679.
    1. Ferré-D’Amaré AR, Zhou K, Doudna JA. Crystal structure of a hepatitis delta virus ribozyme. Nature. [Internet] 1998;395:567–574. doi: 10.1038/26912.
    1. Wu HN, Lai MM. RNA conformational requirements of self-cleavage of hepatitis delta virus RNA. Mol Cell Biol. [Internet] 1990;10:5575–5579. doi: 10.1128/MCB.10.10.5575.
    1. Webb C-HT, Nguyen D, Myszka M, Lupták A, Jimenez RM, Polanco JA, et al. Topological constraints of structural elements in regulation of catalytic activity in HDV-like self-cleaving ribozymes. Sci Rep. [Internet] Nature Publishing Group. 2016;6:28179.
    1. Elena SF, Dopazo J, Florest R, Diener TO, Moya A. Phylogeny of viroids, viroidlike satellite RNAs, and the viroidlike domain of hepatitis 6 virus RNA. Evolution (N Y) 1991;88:5631–5634.
    1. Tseng C-H, Lai MMC. Hepatitis delta virus RNA replication. Viruses. [Internet] 2009;1:818–831. doi: 10.3390/v1030818.
    1. Taylor JM, Hepatitis D. Virus replication. Cold spring Harb. Perspect Med. [Internet] 2015;5:a021568.
    1. Chao M, Wang T-C, Lin C-C, Wang RY-L, Lin W-B, Lee S-E, et al. Analyses of a whole-genome inter-clade recombination map of hepatitis delta virus suggest a host polymerase-driven and viral RNA structure-promoted template-switching mechanism for viral RNA recombination. Oncotarget. [Internet]. 2017; Available from: . Cited 7 Aug 2017.
    1. Flores R, Grubb D, Elleuch A, Nohales M-Á, Delgado S, Gago S. Rolling-circle replication of viroids, viroid-like satellite RNAs and hepatitis delta virus: variations on a theme. RNA Biol. [Internet] 2011;8:200–206. doi: 10.4161/rna.8.2.14238.
    1. Gerlich WH. Medical virology of hepatitis B: how it began and where we are now. Virol J. [Internet] 2013;10:239. doi: 10.1186/1743-422X-10-239.
    1. Watashi K, Urban S, Li W, Wakita T. NTCP and beyond: opening the door to unveil hepatitis B virus entry. Int J Mol Sci. 2014;15:2892–2905. doi: 10.3390/ijms15022892.
    1. Li J, Tong S. From DCPD to NTCP: the long journey towards identifying a functional hepatitis B virus receptor. Clin Mol Hepatol. [Internet] 2015;21:193–199. doi: 10.3350/cmh.2015.21.3.193.
    1. Li W. The hepatitis B virus receptor. Annu Rev Cell Dev Biol. [Internet] 2015;31:annurev-cellbio-100814-125241.
    1. Xia YP, Yeh CT, Ou JH, Lai MM. Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol. [Internet] 1992;66:914–921.
    1. Tavanez JP, Cunha C, Silva MCA, David E, Monjardino J, Carmo-Fonseca M. Hepatitis delta virus ribonucleoproteins shuttle between the nucleus and the cytoplasm. RNA. [Internet] 2002;8:637–646. doi: 10.1017/S1355838202026432.
    1. Alves C, Freitas N, Cunha C. Characterization of the nuclear localization signal of the hepatitis delta virus antigen. Virology. 2008;370:12–21. doi: 10.1016/j.virol.2007.07.034.
    1. Yan H, Li W. Sodium taurocholate cotransporting polypeptide acts as a receptor for hepatitis B and D virus. Dig Dis. 2015;33:388–396. doi: 10.1159/000371692.
    1. Modahl LE, Macnaughton TB, Zhu N, Johnson DL, Lai MM. RNA-dependent replication and transcription of hepatitis delta virus RNA involve distinct cellular RNA polymerases. Mol Cell Biol. [Internet] 2000;20:6030–6039. doi: 10.1128/MCB.20.16.6030-6039.2000.
    1. Greco-Stewart V, Pelchat M. Interaction of host cellular proteins with components of the Hepatitis Delta virus. Viruses. [Internet] 2010;2:189–212. doi: 10.3390/v2010189.
    1. Wu JC, Chiang TY, Shiue WK, Wang SY, Sheen IJ, Huang YH, et al. Recombination of hepatitis D virus RNA sequences and its implications. Mol Biol Evol. [Internet] 1999;16:1622–1632. doi: 10.1093/oxfordjournals.molbev.a026075.
    1. Wang T-C, Chao M. RNA recombination of hepatitis delta virus in natural mixed-genotype infection and transfected cultured cells. J Virol. [Internet] 2005;79:2221–2229. doi: 10.1128/JVI.79.4.2221-2229.2005.
    1. Lin C-C, Lee C-C, Lin S-H, Huang P-J, Li H-P, Chang Y-S, et al. RNA recombination in hepatitis delta virus: identification of a novel naturally occurring recombinant. J Microbiol Immunol Infect. [Internet]. 2015; Available from: . Cited 7 Aug 2017.
    1. Sy BT, Nguyen HM, Toan NL, Song LH, Tong HV, Wolboldt C, et al. Identification of a natural intergenotypic recombinant hepatitis delta virus genotype 1 and 2 in Vietnamese HBsAg-positive patients. J Viral Hepat. [Internet] 2015;22:55–63. doi: 10.1111/jvh.12228.
    1. Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. [Internet] 2016;64:S102–S116. doi: 10.1016/j.jhep.2016.02.013.
    1. Hwang SB, Lai MM. Isoprenylation mediates direct protein-protein interactions between hepatitis large delta antigen and hepatitis B virus surface antigen. J Virol. [Internet] 1993;67:7659–7662.
    1. Radjef N, Gordien E, Ivaniushina V, Gault E, Anaïs P, Drugan T, et al. Molecular phylogenetic analyses indicate a wide and ancient radiation of African hepatitis delta virus, suggesting a deltavirus genus of at least seven major clades. J Virol. [Internet] 2004;78:2537–2544. doi: 10.1128/JVI.78.5.2537-2544.2004.
    1. Dény P. Hepatitis delta virus genetic variability: from genotypes I, II, III to eight major clades? Curr Top Microbiol Immunol. [Internet] 2006;307:151–171.
    1. Le Gal F, Gault E, Ripault M-P, Serpaggi J, Trinchet J-C, Gordien E, et al. Eighth major clade for hepatitis delta virus. Emerg Infect Dis. [Internet] 2006;12:1447–1450. doi: 10.3201/eid1209.060112.
    1. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet. 2011;378:73–85. doi: 10.1016/S0140-6736(10)61931-9.
    1. Farci P. Delta hepatitis: an update. J Hepatol. [Internet] 2003;39(Suppl 1):S212–S219. doi: 10.1016/S0168-8278(03)00331-3.
    1. Rizzetto M, Ponzetto A, Forzani I. Hepatitis delta virus as a global health problem. Vaccine. [Internet]. 1990;8 Suppl:S10-4-3. Available from: . Cited 6 July 2016.
    1. Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, Gerin JL, Casey JL. Geographic distribution and genetic variability of Hepatitis Delta virus genotype I. Virology. [Internet] Academic Press. 1997;234:160–167.
    1. Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci USA. [Internet] 1993;90:9016–9020. doi: 10.1073/pnas.90.19.9016.
    1. Paraná R, Kay A, Molinet F, Viana S, Silva LK, Salcedo JM, et al. HDV genotypes in the western Brazilian Amazon region: a preliminary report. Am J Trop Med Hyg. [Internet] 2006;75:475–479.
    1. Botelho-Souza LF, Souza Vieira D, de Oliveira Dos Santos A, Cunha Pereira AV, Villalobos-Salcedo JM. Characterization of the genotypic profile of Hepatitis Delta virus: isolation of HDV Genotype-1 in the western Amazon region of Brazil. Intervirology. [Internet] 2015;58:166–171. doi: 10.1159/000431040.
    1. Imazeki F, Omata M, Ohto M. Heterogeneity and evolution rates of delta virus RNA sequences. J Virol. [Internet] 1990;64:5594–5599.
    1. Wu JC, Chiang TY, Sheen IJ. Characterization and phylogenetic analysis of a novel hepatitis D virus strain discovered by restriction fragment length polymorphism analysis. J Gen Virol. [Internet] 1998;79(Pt 5):1105–1113. doi: 10.1099/0022-1317-79-5-1105.
    1. Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, Salhi M, et al. Hepatitis delta virus genotypes I and II cocirculate in an endemic area of Yakutia, Russia. J Gen Virol. [Internet] 2001;82:2709–2718. doi: 10.1099/0022-1317-82-11-2709.
    1. Alvarado-Mora MV, Fernandez MFG, Gomes-Gouvêa MS, de Azevedo Neto RS, Carrilho FJ, Pinho JRR. Hepatitis B (HBV), hepatitis C (HCV) and hepatitis delta (HDV) viruses in the Colombian population--how is the epidemiological situation? PLoS One. [Internet] 2011;6:e18888. doi: 10.1371/journal.pone.0018888.
    1. Gomes-Gouvêa MS, do Pereira Soares MC, Guedes de Carvalho Mello IMV, Brito EMF, de Pereira Moia LJM, Bensabath G, et al. Hepatitis D and B virus genotypes in chronically infected patients from the eastern Amazon Basin. Acta Trop. [Internet] 2008;106:149–155. doi: 10.1016/j.actatropica.2008.02.009.
    1. Gomes-Gouvêa MS, Soares MCP, Bensabath G, de Carvalho-Mello IMVG, Brito EMF, Souza OSC, et al. Hepatitis B virus and hepatitis delta virus genotypes in outbreaks of fulminant hepatitis (Labrea black fever) in the western Brazilian Amazon region. J Gen Virol. [Internet] 2009;90:2638–2643. doi: 10.1099/vir.0.013615-0.
    1. Alvarado-Mora MV, Romano CM, Gomes-Gouvêa MS, Gutierrez MF, Carrilho FJ, Pinho JRR. Dynamics of hepatitis D (delta) virus genotype 3 in the Amazon region of South America. Infect Genet Evol. [Internet] 2011;11:1462–1468. doi: 10.1016/j.meegid.2011.05.020.
    1. Ma S-P, Sakugawa H, Makino Y, Tadano M, Kinjo F, Saito A. The complete genomic sequence of hepatitis delta virus genotype IIb prevalent in Okinawa, Japan. J Gen Virol. [Internet] 2003;84:461–464. doi: 10.1099/vir.0.18762-0.
    1. Barros LMF, Gomes-Gouvêa MS, Pinho JRR, Alvarado-Mora MV, Dos Santos A, Mendes-Corrêa MCJ, et al. Hepatitis Delta virus genotype 8 infection in Northeast Brazil: inheritance from African slaves? Virus Res. [Internet] 2011;160:333–339. doi: 10.1016/j.virusres.2011.07.006.
    1. Viana S, Paraná R, Moreira RC, Compri AP, Macedo V. High prevalence of hepatitis B virus and hepatitis D virus in the western Brazilian Amazon. Am J Trop Med Hyg. [Internet] 2005;73:808–814.
    1. Crispim MAE, Fraiji NA, Campello SC, Schriefer NA, Stefani MMA, Kiesslich D. Molecular epidemiology of hepatitis B and hepatitis delta viruses circulating in the western Amazon region, North Brazil. BMC Infect Dis. [Internet] 2014;14:94. doi: 10.1186/1471-2334-14-94.
    1. Fonseca JC, Simonetti SR, Schatzmayr HG, Castejón MJ, Cesário AL, Simonetti JP. Prevalence of infection with hepatitis delta virus (HDV) among carriers of hepatitis B surface antigen in Amazonas state, Brazil. Trans R Soc Trop Med Hyg. [Internet] 1988;82:469–471. doi: 10.1016/0035-9203(88)90166-6.
    1. Vasconcelos M, Pereira DB, Paraná R, Villalobos-Salcedo JM. Clinic and laboratory analysis of patients with hepatitis delta in Amazon region, Brazil. J Med Med Sci. [Internet] 2012;3:263–269.
    1. Braga WSM. Hepatitis B and D virus infection within Amerindians ethnic groups in the Brazilian Amazon: epidemiological aspects. Rev Soc Bras Med Trop. [Internet] 2004;37(Suppl 2):9–13. doi: 10.1590/S0037-86822004000700002.
    1. Braga WSM, da Castilho MC, Borges FG, Leão JRDT, de Martinho ACS, Rodrigues IS, et al. Hepatitis D virus infection in the Western Brazilian Amazon - far from a vanishing disease. Rev Soc Bras Med Trop. [Internet] 2012;45:691–695. doi: 10.1590/S0037-86822012000600007.
    1. Mendes-Correa MC, Gomes-Gouvêa MS, Alvarado-Mora MV, Da Silva MH, Lázari C, Cavalcanti NCS, et al. Hepatitis delta in HIV/HBV co-infected patients in Brazil: is it important? Int J Infect Dis. 2011;15:e828–e832. doi: 10.1016/j.ijid.2011.08.003.
    1. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. [Internet] 2012;32:228–236. doi: 10.1055/s-0032-1323628.
    1. Smedile A, Verme G, Cargnel A, Dentico P, Opolon P, Vergani D, et al. INFLUENCE OF DELTA INFECTION ON SEVERITY OF HEPATITIS B. Lancet. [Internet] Elsevier. 1982;320:945–947. doi: 10.1016/S0140-6736(82)90156-8.
    1. Rizzetto M, Durazzo M. Hepatitis delta virus (HDV) infections. Epidemiological and clinical heterogeneity. J Hepatol. [Internet] 1991;13(Suppl 4):S116–S118. doi: 10.1016/0168-8278(91)90040-I.
    1. Romeo R, Del Ninno E, Rumi M, Russo A, Sangiovanni A, de Franchis R, et al. A 28-year study of the course of hepatitis Δ infection: a risk factor for cirrhosis and Hepatocellular carcinoma. Gastroenterology. 2009;136:1629–1638. doi: 10.1053/j.gastro.2009.01.052.
    1. Grabowski J, Wedemeyer H. Hepatitis delta: immunopathogenesis and clinical challenges. Dig Dis. [Internet] 2010;28:133–138. doi: 10.1159/000282076.
    1. Smedile A, Rizzetto M, Gerin JL. Advances in hepatitis D virus biology and disease. Prog Liver Dis. [Internet] 1994;12:157–175.
    1. Pascarella S, Negro F. Hepatitis D virus: An update. Liver Int. 2011;31:7–21. doi: 10.1111/j.1478-3231.2010.02320.x.
    1. Flodgren E, Bengtsson S, Knutsson M, Strebkova EA, Kidd AH, Alexeyev OA, et al. Recent high incidence of fulminant hepatitis in Samara, Russia: molecular analysis of prevailing hepatitis B and D virus strains. J Clin Microbiol. [Internet] 2000;38:3311–3316.
    1. Casey JL, Niro GA, Engle RE, Vega A, Gomez H, McCarthy M, et al. Hepatitis B virus (HBV)/hepatitis D virus (HDV) coinfection in outbreaks of acute hepatitis in the Peruvian Amazon basin: the roles of HDV genotype III and HBV genotype F. J Infect Dis. [Internet] 1996;174:920–926. doi: 10.1093/infdis/174.5.920.
    1. Schaper M, Rodriguez-Frias F, Jardi R, Tabernero D, Homs M, Ruiz G, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–664. doi: 10.1016/j.jhep.2009.10.036.
    1. Lozano JL, Crespo J, de la Cruz F, Casafont F, Lopez-Arias MJ, Martín-Ramos L, et al. Correlation between hepatitis B viremia and the clinical and histological activity of chronic delta hepatitis. Med Microbiol Immunol. [Internet] 1994;183:159–167. doi: 10.1007/BF00196050.
    1. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European concerted action on viral hepatitis (Eurohep) Gut. [Internet] 2000;46:420–426. doi: 10.1136/gut.46.3.420.
    1. Sánchez-Tapias JM, Mas A, Costa J, Bruguera M, Mayor A, Ballesta AM, et al. Recombinant alpha 2c-interferon therapy in fulminant viral hepatitis. J Hepatol. [Internet] 1987;5:205–210. doi: 10.1016/S0168-8278(87)80574-3.
    1. Buti M, Esteban R, Roggendorf M, Fernandez J, Jardi R, Rashofer R, et al. Hepatitis D virus RNA in acute delta infection: serological profile and correlation with other markers of hepatitis D virus infection. Hepatology. [Internet] 1988;8:1125–1129. doi: 10.1002/hep.1840080526.
    1. Jardi R, Buti M, Rodriguez-Frias F, Garcia-Lafuente A, Sjogren MH, Esteban R, et al. Clinical significance of two forms of IgM antibody to hepatitis delta virus. Hepatology. [Internet] 1991;14:25–28. doi: 10.1002/hep.1840140105.
    1. Buti M, Lopez-Talavera JC, Allende H, Jardi R, Esteban R, Guardia J. Serological diagnosis of chronic delta infection: correlation between serological markers and hepatitis delta virus RNA in hepatic tissue. Prog Clin Biol Res. [Internet] 1993;382:319–323.
    1. Jardi R, Buti M, Rodriguez F, Cotrina M, Allende H, Esteban R, et al. Comparative analysis of serological markers of chronic delta infection: HDV-RNA, serum HDAg and anti-HD IgM. J Virol Methods. [Internet] 1994;50:59–66. doi: 10.1016/0166-0934(94)90163-5.
    1. Jardi R, Buti M, Cotrina M, Rodriguez F, Allende H, Esteban R, et al. Determination of hepatitis delta virus RNA by polymerase chain reaction in acute and chronic delta infection. Hepatology. [Internet] WB Saunders. 1995;21:25–29.
    1. Buti M, Jardi R, Allende H, Cotrina M, Rodriguez F, Viladomiu L, et al. Chronic delta hepatitis: is the prognosis worse when associated with hepatitis C virus and human immunodeficiency virus infections? J Med Virol. [Internet] 1996;49:66–69. doi: 10.1002/(SICI)1096-9071(199605)49:1<66::AID-JMV11>;2-0.
    1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. (London, England) [Internet] NIH Public Access. 2008;371:838–851. doi: 10.1016/S0140-6736(08)60383-9.
    1. Niro GA, Smedile A. Current concept in the pathophysiology of hepatitis delta infection. Curr Infect Dis Rep. [Internet] 2012;14:9–14. doi: 10.1007/s11908-011-0233-5.
    1. Verme G, Amoroso P, Lettieri G, Pierri P, David E, Sessa F, et al. A histological study of hepatitis delta virus liver disease. Hepatology. [Internet] 1986;6:1303–1307. doi: 10.1002/hep.1840060613.
    1. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. [Internet] 2014;60:87–97. doi: 10.1002/hep.27102.
    1. Rizzetto M, Alavian SM. Hepatitis delta: the rediscovery. Clin Liver Dis. 2013;17:475–487. doi: 10.1016/j.cld.2013.05.007.
    1. Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. [Internet] 2012;32:237–244. doi: 10.1055/s-0032-1323629.
    1. Heller T, Rotman Y, Koh C, Clark S, Haynes-Williams V, Chang R, et al. Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther. [Internet] 2014;40:93–104. doi: 10.1111/apt.12788.
    1. Niro GA, Ciancio A, Tillman HL, Lagget M, Olivero A, Perri F, et al. Lamivudine therapy in chronic delta hepatitis: a multicentre randomized-controlled pilot study. Aliment Pharmacol Ther. [Internet] 2005;22:227–232. doi: 10.1111/j.1365-2036.2005.02542.x.
    1. Erhardt A, Gerlich W, Starke C, Wend U, Donner A, Sagir A, et al. Treatment of chronic hepatitis delta with pegylated interferon-α2b. Liver Int. [Internet] Blackwell Publishing Ltd. 2006;26:805–810.
    1. Lau DT, Doo E, Park Y, Kleiner DE, Schmid P, Kuhns MC, et al. Lamivudine for chronic delta hepatitis. Hepatology. [Internet]. W.B. Saunders. 1999;30:546–549.
    1. Kabaçam G, Onder FO, Yakut M, Seven G, Karatayli SC, Karatayli E, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. [Internet] 2012;55:645–650. doi: 10.1093/cid/cis459.
    1. Gunsar F, Akarca US, Ersoz G, Kobak AC, Karasu Z, Yuce G, et al. Two-year interferon therapy with or without ribavirin in chronic delta hepatitis. Antivir Ther. [Internet] 2005;10:721–726.
    1. Yurdaydin C, Bozkaya H, Karaaslan H, Onder FO, Erkan OE, Yalçin K, et al. A pilot study of 2 years of interferon treatment in patients with chronic delta hepatitis. J Viral Hepat. [Internet] 2007;14:812–816. doi: 10.1111/j.1365-2893.2007.00875.x.
    1. Samiullah S, Bikharam D, Nasreen Treatment of chronic hepatitis delta virus with peg-interferon and factors that predict sustained viral response. World J Gastroenterol. [Internet] Baishideng Publishing Group Inc. 2012;18:5793–5798. doi: 10.3748/wjg.v18.i40.5793.
    1. Gheorghe L, Iacob S, Simionov I, Vadan R, Constantinescu I, Caruntu F, et al. Weight-based dosing regimen of peg-interferon α-2b for chronic hepatitis delta: a multicenter Romanian trial. J Gastrointestin Liver Dis. [Internet] 2011;20:377–382.
    1. Koh C, Canini L, Dahari H, Zhao X, Uprichard SL, Haynes-Williams V, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. [Internet] 2015;15:1167–1174. doi: 10.1016/S1473-3099(15)00074-2.
    1. Rizzetto M, Niro GA. Myrcludex B, a novel therapy for chronic hepatitis D? J Hepatol. [Internet] 2016;65:465–466. doi: 10.1016/j.jhep.2016.06.014.
    1. Bogomolov P, Alexandrov A, Voronkova N, Macievich M, Kokina K, Petrachenkova M, et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: first results of a phase Ib/IIa study. J Hepatol. [Internet] 2016;65:490–498. doi: 10.1016/j.jhep.2016.04.016.
    1. Abeywickrama-Samarakoon N, Cortay J-C, Dény P. The hepatitis D satellite virus of hepatitis B virus: half-opening a new era to control viral infection? Curr Opin Infect Dis. [Internet] 2016;29:645–653. doi: 10.1097/QCO.0000000000000321.
    1. Rizzetto M, Ciancio A. The prenylation inhibitor, lonafarnib: a new therapeutic strategy against hepatitis delta. Lancet Infect Dis. [Internet] 2015;15:1119–1120. doi: 10.1016/S1473-3099(15)00155-3.
    1. Giersch K, Homs M, Volz T, Helbig M, Allweiss L, Lohse AW, et al. Both interferon alpha and lambda can reduce all intrahepatic HDV infection markers in HBV/HDV infected humanized mice. Sci Rep. [Internet] 2017;7:3757. doi: 10.1038/s41598-017-03946-9.
    1. Borzacov LMP, de Figueiredo Nicolete LD, Souza LFB, dos Santos AO, Vieira DS, Salcedo JMV. Treatment of hepatitis delta virus genotype 3 infection with peg-interferon and entecavir. Int J Infect Dis. [Internet] 2016;46:82–88. doi: 10.1016/j.ijid.2016.03.017.
    1. Ciancio A, Rizzetto M. Chronic hepatitis D at a standstill: where do we go from here? Nat Rev Gastroenterol Hepatol. [Internet] 2014;11:68–71. doi: 10.1038/nrgastro.2013.164.
    1. Manesis EK, Vourli G, Dalekos G, Vasiliadis T, Manolaki N, Hounta A, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59:949–956. doi: 10.1016/j.jhep.2013.07.005.
    1. Abbas Z, Qureshi M, Hamid S, Jafri W. Hepatocellular carcinoma in hepatitis D: does it differ from hepatitis B monoinfection? Saudi J Gastroenterol. [Internet] 2012;18:18–22. doi: 10.4103/1319-3767.91731.
    1. Heidrich B, Manns MP, Wedemeyer H. Treatment options for hepatitis delta virus infection. Curr Infect Dis Rep. [Internet] 2013;15:31–38. doi: 10.1007/s11908-012-0307-z.
    1. Ji J, Sundquist K, Sundquist J. A population-based study of hepatitis D virus as potential risk factor for hepatocellular carcinoma. J Natl Cancer Inst. [Internet] 2012;104:790–792. doi: 10.1093/jnci/djs168.
    1. Freitas N, Salisse J, Cunha C, Toshkov I, Menne S, Gudima SO. Hepatitis delta virus infects the cells of hepadnavirus-induced hepatocellular carcinoma in woodchucks. Hepatology. [Internet] 2012;56:76–85. doi: 10.1002/hep.25663.
    1. Cross TJS, Rizzi P, Horner M, Jolly A, Hussain MJ, Smith HM, et al. The increasing prevalence of hepatitis delta virus (HDV) infection in South London. J Med Virol. [Internet] 2008;80:277–282. doi: 10.1002/jmv.21078.
    1. Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. [Internet] 2010;30:430–437. doi: 10.1111/j.1478-3231.2009.02140.x.
    1. Wranke A, Heidrich B, Ernst S, Calle Serrano B, Caruntu FA, Curescu MG, et al. Anti-HDV IgM as a marker of disease activity in hepatitis delta. PLoS One. [Internet] 2014;9:e101002. doi: 10.1371/journal.pone.0101002.
    1. Farci P, Roskams T, Chessa L, Peddis G, Mazzoleni AP, Scioscia R, et al. Long-term benefit of interferon α therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–1749. doi: 10.1053/j.gastro.2004.03.017.
    1. Madejón A, Cotonat T, Bartolomé J, Castillo I, Carreño V. Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: utility of polymerase chain reaction in monitoring antiviral response. Hepatology. [Internet] 1994;19:1331–1336. doi: 10.1002/hep.1840190602.
    1. Garripoli A, Di Marco V, Cozzolongo R, Costa C, Smedile A, Fabiano A, et al. Ribavirin treatment for chronic hepatitis D: a pilot study. Liver. [Internet] 1994;14:154–157. doi: 10.1111/j.1600-0676.1994.tb00065.x.
    1. Yurdaydin C, Bozkaya H, Gürel S, Tillmann HL, Aslan N, Okçu-Heper A, et al. Famciclovir treatment of chronic delta hepatitis. J Hepatol. 2002;37:266–271. doi: 10.1016/S0168-8278(02)00162-9.
    1. Castelnau C, Le Gal F, Ripault M-P, Gordien E, Martinot-Peignoux M, Boyer N, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. [Internet] 2006;44:728–735. doi: 10.1002/hep.21325.
    1. Niro GA, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis delta. Hepatology. [Internet] 2006;44:713–720. doi: 10.1002/hep.21296.
    1. Canbakan B, Senturk H, Tabak F, Akdogan M, Tahan V, Mert A, et al. Efficacy of interferon alpha-2b and lamivudine combination treatment in comparison to interferon alpha-2b alone in chronic delta hepatitis: a randomized trial. J Gastroenterol Hepatol. [Internet] 2006;21:657–663. doi: 10.1111/j.1440-1746.2006.04082.x.
    1. Yurdaydin C, Bozkaya H, Onder FO, Sentürk H, Karaaslan H, Akdoğan M, et al. Treatment of chronic delta hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. [Internet] 2008;15:314–321. doi: 10.1111/j.1365-2893.2007.00936.x.
    1. Ormeci N, Bölükbaş F, Erden E, Coban S, Ekiz F, Erdem H, et al. Pegylated interferon alfa-2B for chronic delta hepatitis: 12 versus 24 months. Hepatogastroenterology. [Internet] 2011;58:1648–1653.
    1. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. [Internet] 2011;364:322–331. doi: 10.1056/NEJMoa0912696.
    1. Karaca C, Soyer OM, Baran B, Ormeci AC, Gokturk S, Aydin E, et al. Efficacy of pegylated interferon-α treatment for 24 months in chronic delta hepatitis and predictors of response. Antivir Ther. [Internet] 2013;18:561–566. doi: 10.3851/IMP2381.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren